Baxter corporate credit rating downgraded by S&P Standard & Poor's lowered its corporate credit and unsecured debt ratings on Baxter to 'A' from 'A+', citing the company's weakened financial risk profile following the proposed acquisition of Gambro.
News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.
Baxter granted authorization by European Commission for use of HyQvia Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the European Commission has granted Baxter marketing authorization in all European Union Member States for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxter will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014.